ER-positive Breast Cancer trials recruiting in Massachusetts

All ER-positive Breast Cancer trials nationally

Cities in Massachusetts

Recruiting trials in Massachusetts

• DATO-BASE: DATOpotamab-deruxtecan for Breast Cancer Brain metAstaSEs
  NCT06176261 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Massachusetts: Boston
• Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
  NCT07085767 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Massachusetts: Burlington
• Phase 1b Study of OP-1250 (Palazestrant) in Combination With Ribociclib, Alpelisib, Everolimus, or Atirmociclib in ER+, HER2- Breast Cancer
  NCT05508906 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · Massachusetts: Boston
• Supporting Health Including Endocrine Treatment for Long Duration
  NCT07482384 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 49 Years · Sex: Female · Massachusetts: Boston